Key result
CHA₂DS₂-VASc ≥5 linked to ~6.6-fold higher thromboembolic risk in apixaban-treated AF patients.
Why the study?
Real-world evidence on apixaban in patients with AF at very high thromboembolic risk (CHA₂DS₂-VASc ≥ 5) is limited, particularly from the Middle East.
Does a very high baseline thromboembolic risk (CHA₂DS₂-VASc ≥5 vs 0–4) or prescribed apixaban dose (2.5 mg vs 5 mg twice daily) affect thromboembolic events, bleeding, and in-hospital mortality in apixaban-treated adults with atrial fibrillation?
Cohort (n=596)
No
Does a very high baseline thromboembolic risk (CHA₂DS₂-VASc ≥5 vs 0–4) or prescribed apixaban dose (2.5 mg vs 5 mg twice daily) affect thromboembolic events, bleeding, and in-hospital mortality in apixaban-treated adults with atrial fibrillation?
In apixaban-treated patients with atrial fibrillation in Saudi Arabia, a CHA₂DS₂-VASc score ≥5 is strongly associated with higher in-hospital mortality and (after accounting for baseline stroke overlap) bleeding, highlighting the need for close clinical monitoring in this very high-risk population.
Answers are grounded in this paper and cite their sources.
May warrant closer monitoring in apixaban-treated AF patients with CHA₂DS₂-VASc ≥5; extends score utility but leaves optimal strategies open.
Background Real-world evidence on apixaban in patients with atrial fibrillation (AF) at very high thromboembolic risk (CHA₂DS₂-VASc ≥ 5) is limited, particularly from the Middle East. We compared clinical outcomes between apixaban-treated patients with CHA₂DS₂-VASc scores ≥ 5 and 0–4, and between prescribed doses within the very high-risk group. Methods In this retrospective cohort study at a tertiary referral center in Makkah, Saudi Arabia, adults with AF treated with apixaban between January 2019 and December 2024 were grouped by baseline CHA₂DS₂-VASc score. Outcomes were documented thromboembolic events, bleeding of any severity, and in-hospital mortality. Odds ratios (ORs) were estimated by unadjusted and multivariable logistic regression. A sensitivity analysis excluded patients with a recorded prior stroke. Results Of 596 patients, 175 (29.4%) had scores ≥ 5. Thromboembolic events (31.4% vs 7.1%; adjusted OR 6.6, 95% CI 3.9–11.0) and in-hospital mortality (14.3% vs 1.7%; adjusted OR 7.7, 95% CI 3.2–18.5) were more frequent with scores ≥ 5, whereas bleeding did not differ significantly (54.9% vs 46.8%; adjusted OR 1.3, 95% CI 0.9–1.9). Of 68 patients with a recorded prior stroke, 58 also had a documented thromboembolic event; after their exclusion, thromboembolic events no longer differed (5.2% vs 5.1%), whereas bleeding (adjusted OR 3.2, 95% CI 2.0–5.1) and mortality (adjusted OR 8.7, 95% CI 3.4–22.1) were more frequent with scores ≥ 5. Among very high-risk patients, prescribed dose (2.5 mg, n = 73; 5 mg, n = 102, twice daily) was not significantly associated with any outcome. Conclusions A CHA₂DS₂-VASc score ≥ 5 was associated with higher in-hospital mortality among apixaban-treated patients with AF. The excess of thromboembolic events was confined to patients with a recorded prior stroke and may reflect overlap between baseline history and outcome recording. Prescribed dose was not associated with outcomes, although dose appropriateness could not be assessed. Larger studies with complete dosing criteria and event timing are needed.
No takes yet. Share an insight, caveat, or question.
Alshehri et al. (2026) conducted a cohort in Non-valvular atrial fibrillation treated with apixaban (n=596). Very high thromboembolic risk (CHA₂DS₂-VASc score ≥5) vs. Lower thromboembolic risk (CHA₂DS₂-VASc score 0–4) was evaluated on Documented thromboembolic events (stroke or systemic embolic event) (OR 6.6, 95% CI 3.9-11.0). A CHA₂DS₂-VASc score ≥5 in apixaban-treated AF patients was associated with higher documented thromboembolic events and in-hospital mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: